Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

405.10INR
7:09am GMT
Change (% chg)

Rs4.45 (+1.11%)
Prev Close
Rs400.65
Open
Rs400.95
Day's High
Rs408.95
Day's Low
Rs399.90
Volume
337,946
Avg. Vol
987,132
52-wk High
Rs560.00
52-wk Low
Rs378.55

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says U.S.FDA Completed Inspection At Co's Dabhasa API Facility​
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Cadila Healthcare Ltd ::SAYS USFDA ‍ SUCCESSFULLY COMPLETED INSPECTION AT CO'S DABHASA API FACILITY​.SAYS USFDA DID NOT ISSUE ANY OBSERVATION AFTER INSPECTION.  Full Article

Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Glenmark Pharmaceuticals Ltd ::LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA.  Full Article

Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clomipramine Hydrochloride Capsules
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR CLOMIPRAMINE HYDROCHLORIDE CAPSULES USP.SAYS CAPSULES TO BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY IN AHMEDABAD.  Full Article

Cadila Healthcare Says ‍Zydus Gets U.S.FDA Nod For Drug to Treat Hypertension, Chest Pain
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Cadila Healthcare Ltd ::SAYS ‍ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR NIFEDIPINE EXTENDED-RELEASE TABLETS USP​.DRUG USED TO TREAT HYPERTENSION, CHEST PAIN WILL BE MANUFACTURED AT CO'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says ‍Zydus Got USFDA Nod For Two Drugs
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Cadila Healthcare Ltd ::‍ZYDUS GETS FINAL APPROVAL FROM USFDA FOR PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE TABLETS & NITROFURANTOIN CAPSULES USP (MACROCRYSTALS)​.PRAMIPEXOLE DIHYDROCHLORIDE TO TREAT SYMPTOMS OF PARKINSON'S DISEASE; NITROFURANTOIN TO TREAT ACUTE URINARY TRACT INFECTION.SAYS BOTH DRUGS TO BE MANUFACTURED AT CO'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD‍​.  Full Article

Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clozapine Tablets
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GET FINAL NOD FROM U.S. FDA FOR CLOZAPINE TABLETS USP.DRUG USED TO TREAT SCHIZOPHRENIA ; DRUG TO BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Tentative Approval From U.S. FDA For Pregabalin Capsules
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS TENTATIVE APPROVAL FROM U.S. FDA FOR PREGABALIN CAPSULES.SAYS CAPSULE TO BE MANUFACTURED AT GROUP'S FORMULATIONS FACILITY AT MORAIYA, AHMEDABAD.  Full Article

Cadila Healthcare's Zydus, ICMR Launch Diagnostic Kits To Detect Rare Infectious Diseases
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Cadila Healthcare Ltd ::INDIAN COUNCIL OF MEDICAL RESEARCH, ZYDUS LAUNCH DIAGNOSTIC KITS TO DETECT NEGLECTED INFECTIOUS DISEASES IN LIVESTOCK.SAYS KITS TO BE MADE, MARKETED BY ZYDUS DIAGNOSTICS.  Full Article

Cadila Healthcare says ‍Zydus gets USFDA approval for minocycline hydrochloride extended-release tablets​
Friday, 24 Nov 2017 

Nov 24 (Reuters) - Cadila Healthcare Ltd :Says ‍Zydus receives approval from USFDA for minocycline hydrochloride extended - release tablets.Product to be manufactured at formulations manufacturing facilty at Moraiya, Ahmedabad‍​​.  Full Article

Cadila Healthcare says Zydus gets tentative approval from U.S. FDA for tadalafil tablets USP
Thursday, 23 Nov 2017 

Nov 23 (Reuters) - Cadila Healthcare Ltd :Says Zydus gets tentative approval from USFDA for tadalafil tablets USP.Says drug to be manufactured at group's formulations manufcaturing facility at Moraiya, Ahmedabad.  Full Article

Indian shares bounce back amid global recovery

Feb 12 Indian shares rose on Monday, recovering from their biggest weekly drop since August, as a battered healthcare sector recouped, although State Bank of India slumped after posting a surprise quarterly loss.